Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex
Wiebke Theilmann, Birthe Gericke, Alina Schidlitzki, Syed Muhammad Muneeb Anjum, Saskia Borsdorf, Timon Harries, Steven L. Roberds, Dean J. Aguiar, Daniela Brunner, Steven C. Leiser, Dekun Song, Doriano Fabbro, Petra Hillmann, Matthias P. Wymann, Wolfgang Löscher
Topics & Concepts
mTORC1EverolimusTuberous sclerosisEpilepsyPharmacologyPI3K/AKT/mTOR pathwayMedicineSirolimusMechanistic target of rapamycinTolerabilityAdverse effectOncologyChemistryInternal medicineSignal transductionPathologyPsychiatryBiochemistryTuberous Sclerosis Complex ResearchPI3K/AKT/mTOR signaling in cancerPolyamine Metabolism and Applications